Detalhe da pesquisa
1.
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic.
Oncologist
; 26(4): 341-347, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355953
2.
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Future Oncol
; 14(26): 2691-2699, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30207488
3.
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Future Oncol
; 12(4): 493-502, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26776493
4.
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
J Urol
; 193(6): 1905-10, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25433306
5.
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
BJU Int
; 115(5): 764-71, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24988879
6.
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Future Oncol
; 11(21): 2881-91, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26436290
7.
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Future Oncol
; 10(6): 975-83, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295376
8.
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Lancet Oncol
; 13(8): 810-6, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22819172
9.
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Eur J Cancer
; 155: 56-63, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34358777
10.
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Cancer Immunol Immunother
; 59(4): 553-61, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19779715
11.
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial.
Tumori
; : 300891620915786, 2020 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32364051
12.
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
Eur Urol
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38772788
13.
Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.
Medicine (Baltimore)
; 95(2): e2299, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26765406
14.
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Oncotarget
; 7(26): 40085-40094, 2016 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27223078
15.
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Clin Genitourin Cancer
; 14(1): 48-55, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26382222
16.
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Urol Oncol
; 33(6): 265.e15-21, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25907622
17.
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Eur Urol
; 68(1): 147-53, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25457020
18.
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Eur J Cancer
; 49(9): 2134-42, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23518211